© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Venetoclax, known in research and clinical settings as ABT-199, stands out as a selective B-cell lymphoma 2 (BCL-2) inhibitor. Chemically, Venetoclax presents as a molecular compound designed to target and inhibit BCL-2 proteins, a key factor in regulating apoptosis in cancer cells, especially forms of leukemia and lymphoma. As a relatively modern tool in targeted therapy, Venetoclax’s development relied on direct insights from proteomic and biochemical analysis, which nudged its journey through research pipelines into the hands of specialists managing difficult blood cancers.
This compound occurs as a solid under standard laboratory conditions and appears as an off-white to pale yellow powder. Structurally speaking, Venetoclax reveals a dense and intricate molecular backbone, which hinges on a distinct binding motif critical for high-affinity contact with BCL-2. The chemical formula stands as C45H50ClN7O7S, with a molecular weight hovering around 868.44 g/mol. Its shape sometimes takes on a crystalline appearance—that is, you can observe its particles exhibit crystals and flakes depending on methods used during synthesis or purification. Density measurements hover near 1.3 g/cm³, which means a given mass occupies a relatively compact volume.
Venetoclax remains stable within a well-defined range of temperatures, typically storing at -20°C to preserve its integrity. Its solubility tells an important part of its laboratory story. In DMSO, it dissolves well, while its performance in water leads to very limited solubility. This trait dictates how researchers formulate stock solutions for in vitro and in vivo experiments—commonly as concentrated DMSO solutions for later dilution into other media. Researchers preparing Venetoclax for bioassay application or preclinical mixtures rely on powders or pearls, all offering consistent, fine material for accurate dosing and blending. Toxicology data place it squarely among compounds demanding careful handling, highlighted by its categorization as a hazardous chemical suitable for trained hands only. Beyond lab handling, safe disposal practices and stringent exposure controls remain standard advice due to the compound’s biological activity and potential harm upon inhalation, ingestion, or skin contact.
The international Harmonized System (HS) Code for Venetoclax falls under HS 2934999099, nestled with other specialized organic compounds used in medical research and pharmaceutical development. Transportation of this compound relies on clear labeling and compliance with regional controls for hazardous and sensitive materials.
Venetoclax’s distribution covers several material formats to suit varied application needs. The bulk of research and pharmaceutical channels offer it as a loose powder or fine flake, selected for uniform mixing and weighing accuracy. Some specialized suppliers deliver pearlized or microcrystalline variants, facilitating slow dissolution or other unique research requirements. Rarely, select manufacturers offer Venetoclax in pre-dissolved liquid or solution format, mostly at defined concentrations in DMSO or ethanol. These solutions provide convenience and minimize handling risk but call for cold-chain logistics and close control over storage temperature and light exposure to retain stability.
Any researcher working with Venetoclax faces a suite of potential hazards typical to potent, targeted therapeutics. GHS labeling flags its toxic and potentially carcinogenic nature, mandating gloves, mask, and eye protection in all environments. Preparation occurs inside fume hoods to manage dust and vapor hazards, while staff receive instruction in the correct use of spill kits and neutralizing agents for accidental release. Documented incidents in large-scale facilities highlight the potential harm if protocols lapse. In personal experience, even trace powder from failed cap closures in the lab required immediate isolation and full decontamination. These episodes reinforce why handling stays limited to designated experts with strong chemical and biological safety training.
Sourcing Venetoclax starts at a limited pool of raw chemical providers, each specializing in high-purity intermediates and advanced reaction controls. Consecutive steps of synthesis, such as formation of the core scaffold and specific halogenation patterns, demand skill to maintain purity and prevent isomer contamination. Only a handful of certified global suppliers hold the expertise to generate material at the pharmaceutical grade required for downstream formulation. Stock solutions, once prepared, offer reliable stability for up to one month at -20°C under desiccated conditions, which matches best practices found in most modern research protocols. Consistently, I have found best results with regular refreshing of stock to avoid unseen degradation or precipitation.
Reducing risk starts with a robust chain of custody from raw material supplier through delivery, storage, and use. Routine batch testing for purity and identity, combined with closed-loop handling protocols, minimizes both risk and wastage. Digital tracking through batch numbers and QR-coded vials helps researchers monitor shelf life and use history at a glance. For groups using Venetoclax at scale, investment in automated dosing and dispense systems cuts down on spills and accidental exposure. Institutions who prioritize well-staffed chemical safety offices and regular refresher training keep harm low, while clear documentation for regulatory bodies proves essential. Bringing down long-term costs and risks means building habits of transparency and careful stewardship into the daily workflow.
